A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (ACCL2031)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been recently diagnosed with a brain tumor and are planning to undergo radiation therapy. This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or have come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor.

Additional information can be found here: A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor - Full Text View - ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT 04939597)